Abstract

In polyglutamine (polyQ) diseases including Huntington's disease (HD), mutant proteins containing expanded polyQ stretch form aggregates in neurons. Genetic or RNAi screenings in yeast, C. elegans or Drosophila have identified multiple genes modifying polyQ aggregation, a few of which are confirmed effective in mammals. However, the overall molecular mechanism underlying polyQ protein aggregation in mammalian cells still remains obscure. We here perform RNAi screening in mouse neuro2a cells to identify mammalian modifiers for aggregation of mutant huntingtin, a causative protein of HD. By systematic cell transfection and automated cell image analysis, we screen ∼12000 shRNA clones and identify 111 shRNAs that either suppress or enhance mutant huntingtin aggregation, without altering its gene expression. Classification of the shRNA-targets suggests that genes with various cellular functions such as gene transcription and protein phosphorylation are involved in modifying the aggregation. Subsequent analysis suggests that, in addition to the aggregation-modifiers sensitive to proteasome inhibition, some of them, such as a transcription factor Tcf20, and kinases Csnk1d and Pik3c2a, are insensitive to it. As for Tcf20, which contains polyQ stretches at N-terminus, its binding to mutant huntingtin aggregates is observed in neuro2a cells and in HD model mouse neurons. Notably, except Pik3c2a, the rest of the modifiers identified here are novel. Thus, our first large-scale RNAi screening in mammalian system identifies previously undescribed genetic players that regulate mutant huntingtin aggregation by several, possibly mammalian-specific mechanisms.

Highlights

  • Polyglutamine diseases are adult-onset hereditary neurodegenerative disorders

  • To identify modifiers of mutant Htt aggregation in mammalian cells, we performed short hairpin RNA (shRNA) screening using mouse neuro2a cells that inducibly expressed exon 1 of Htt (Nhtt) containing a 150Q tagged with an EGFP at its C-terminus (Nhtt150Q-EGFP), under the control of ponasterone A [35]. shRNA libraries were purchased from Open Biosystems, in which shRNA clones were supplied as E. coli glycerol stocks in 96 well plate-formats

  • Neuro2a cells were seeded on 96 well plates and transiently transfected with shRNA clones

Read more

Summary

Introduction

Polyglutamine (polyQ) diseases are adult-onset hereditary neurodegenerative disorders. These include Huntington’s disease (HD), spinocerebellar ataxias (SCA1, 2, 3, 6, 7, 17), dentatorubralpallidoluysian atrophy (DRPLA) and spinobulbar muscular atrophy (SBMA). The polyQ diseases are caused by expansion of CAG repeats in certain causative genes. The mutant proteins containing expanded polyQ stretch are misfolded and aggregated, leading to formation of nuclear inclusions in neurons [1,2]. The polyQ protein aggregation accompanies sequestration of several cellular components such as transcription factors [3,4,5,6,7] and RNA binding proteins [8,9], leading to dysregulation of gene expression during neurodegeneration [10,11,12]. Examination of molecular mechanisms underlying polyQ aggregation is one of the effective strategies for understanding pathomechanism of and searching therapeutic targets for polyQ diseases

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call